+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
FEMALE
ID04501523

Phase II Study Using Circulating Tumor DNA to Guide Post-Surgery Boost Treatment After Chemotherapy in Triple-Negative Breast Cancer

Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2023-02-21

460

Participants Needed

1

Research Sites

261 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying triple-negative breast cancer TNBC, focusing on how circulating tumor DNA ctDNA levels after treatment can predict the risk of cancer returning. This trial aims to improve outcomes for TNBC patients by identifying those with high relapse risk through ctDNA testing and offering additional boost therapy post-surgery. The study is a phase II clinical trial evaluating this approach in patients who have undergone neoadjuvant chemotherapy NAC. Participants who test positive for ctDNA and have not achieved a complete pathological response non-pCR after NAC are randomly assigned to receive either a combination of tislelizumab, an anti-PD1 antibody given at 200 mg every three weeks for one year, plus capecitabine, or standard treatment with capecitabine alone at 600-750 mgm2 twice daily continuously for one year. Those who are ctDNA positive but have achieved a complete pathological response receive capecitabine. The trial also includes a follow-up group receiving standard care. During the study, participants will have frequent blood tests every three months and other evaluations to monitor disease status and treatment effects. Researchers will measure disease-free survival over five years as the primary outcome, along with overall survival, remission rates, brain metastasis, response rates, safety, and relapse rates over periods extending up to ten years. The total follow-up includes long-term monitoring to understand how well patients do after treatment.

CONDITIONS

Brief Title

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC

Research Team

S

Shunying Li, MD

Y

Yudong Li, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here